Arcturus Therapeutics Holdings Inc. (ARCT) has a negative trailing P/E of -3.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -29.05%.
Criteria proven by this page:
Overall SharesGrow Score: 52/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -2.4 | 3.70 | 1.23 | 2.84 | - |
| 2017 | -2.3 | 0.05 | 0.73 | 1.90 | - |
| 2018 | -2.1 | 0.05 | 3.34 | 2.90 | - |
| 2019 | -5.0 | 3.63 | 5.09 | 6.31 | - |
| 2020 | -12.2 | -0.18 | 2.22 | 92.34 | - |
| 2021 | -4.8 | -0.04 | 4.27 | 78.81 | - |
| 2022 | 48.0 | -0.46 | 1.66 | 2.18 | - |
| 2023 | -28.2 | 0.07 | 3.01 | 5.32 | - |
| 2024 | -5.7 | -0.03 | 1.90 | 3.31 | - |
| 2025 | -2.6 | 0.13 | 0.78 | 2.50 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-6.25 | $20.38M | $-24.6M | -120.7% |
| 2017 | $-3.53 | $13M | $-10.9M | -83.9% |
| 2018 | $-2.16 | $15.75M | $-21.79M | -138.3% |
| 2019 | $-2.13 | $20.79M | $-25.72M | -123.7% |
| 2020 | $-3.51 | $9.54M | $-71.36M | -748.1% |
| 2021 | $-7.86 | $12.36M | $-206.86M | -1673.8% |
| 2022 | $0.35 | $205.76M | $9.35M | 4.5% |
| 2023 | $-1.12 | $157.75M | $-29.73M | -18.8% |
| 2024 | $-3.00 | $138.39M | $-80.94M | -58.5% |
| 2025 | $-2.40 | $67.22M | $-65.78M | -97.9% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-4.04 | $-4.98 – $-2.78 | $37.13M | $27.78M – $52.89M | 9 |
| 2027 | $-4.20 | $-6.02 – $-0.25 | $40.6M | $10.86M – $124.86M | 9 |
| 2028 | $-1.47 | $-6.92 – $18.71 | $139.36M | $132.27M – $146.45M | 7 |
| 2029 | $-2.39 | $-9.25 – $-0.49 | $106.64M | $41.26M – $341.51M | 2 |
| 2030 | $-0.58 | $-2.24 – $-0.12 | $170.11M | $65.81M – $544.75M | 5 |
